X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds from the offering for its ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimer’s disease.
Lead Product(s): Allogeneic Medicinal Signaling Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2024
Details:
The Company intends to use the net proceeds from the offering for its ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimer’s disease.
Lead Product(s): Allogeneic Medicinal Signaling Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $5.25 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 08, 2024
Details:
The net proceeds will be used for company's ongoing clinical and regulatory development of Lomecel-B (allogeneic medicinal signaling cell therapy) for the treatment of several disease states and indications, including HLHS and Alzheimer’s Disease.
Lead Product(s): Allogeneic Medicinal Signaling Cell Therapy
Therapeutic Area: Neurology Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2023
Details:
Lomecel-B is a preparation of multipotent stem and progenitor cells isolated from bone marrow of young healthy adults. It is being evaluated in phase 2 clinical trials for the treatment of mild alzheimer's disease.
Lead Product(s): Allogeneic Medicinal Signaling Cell Therapy
Therapeutic Area: Neurology Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
Longeveron will fund the ongoing clinical and regulatory development of Lomecel-B (longeveron mesenchymal stem cell), an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors.
Lead Product(s): Longeveron Mesenchymal Stem Cell
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 13, 2023
Details:
Longeveron currently intends to use the net proceeds from the offering to fund the ongoing clinical and regulatory development of Lomecel-B (mesenchymal stem cell) and for capital expenditures, working capital and general corporate purposes.
Lead Product(s): Longeveron Mesenchymal Stem Cell
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lomecel-B
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 12, 2023
Details:
Lomecel-B is an allogeneic MSC therapy product isolated from the bone marrow of young, healthy adult donors. It is a pro-vascular,pro-regenerative, anti-inflammatory, and tissue repair and healing effects. It is being investigated for the treatment of mild Alzheimer’s disease.
Lead Product(s): Allogeneic Medicinal Signaling Cell Therapy
Therapeutic Area: Neurology Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Lomecel-B is an allogeneic MSC therapy product isolated from the bone marrow of young, healthy adult donors. It is a pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects. It is being investigated for hypoplastic left heart syndrome.
Lead Product(s): Allogeneic Medicinal Signaling Cell Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2023
Details:
Lomecel-B is an allogeneic MSC therapy product isolated from the bone marrow of young, healthy adult donors. It is a pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects. It is being investigated for hypoplastic left heart syndrome.
Lead Product(s): Allogeneic Medicinal Signaling Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lomecel-B
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Lomecel-B, an allogeneic MSC therapy product isolated from the bone marrow of young, healthy adult donors. It is a pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects, it is being developed for aging-related frailty.
Lead Product(s): Longeveron Mesenchymal Stem Cell
Therapeutic Area: Musculoskeletal Product Name: Lomecel-B
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
